Israeli drug development company BioLineRX has announced that it will receive an $8 million investment from OrbiMed Israel Partners LP. BioLineRX says that it will use the funds to continue the development of its clinical and pre-clinical state therapeutic assets.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments